Previous close | 6.94 |
Open | 6.89 |
Bid | 6.51 x 100 |
Ask | 6.59 x 100 |
Day's range | 6.49 - 6.95 |
52-week range | 3.45 - 10.83 |
Volume | |
Avg. volume | 404,429 |
Market cap | 286.154M |
Beta (5Y monthly) | 1.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.51 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 27 Jan 2010 |
1y target est | 13.67 |
ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call
AxoGen, Inc. ( NASDAQ:AXGN ) is possibly approaching a major achievement in its business, so we would like to shine...
Director Gregory Freitag has sold 25,000 shares of Axogen Inc (NASDAQ:AXGN) on March 7, 2024, according to a recent SEC Filing.